Nothing Special   »   [go: up one dir, main page]

DK1539977T3 - Fremstilling af tiacumicin - Google Patents

Fremstilling af tiacumicin Download PDF

Info

Publication number
DK1539977T3
DK1539977T3 DK03784766.2T DK03784766T DK1539977T3 DK 1539977 T3 DK1539977 T3 DK 1539977T3 DK 03784766 T DK03784766 T DK 03784766T DK 1539977 T3 DK1539977 T3 DK 1539977T3
Authority
DK
Denmark
Prior art keywords
nutrient medium
thiacumicin
group
microorganism
tiacumicin
Prior art date
Application number
DK03784766.2T
Other languages
English (en)
Inventor
Chi-Jen Frank Du
Ming-His Chiou
Mei-Chiao Wu
Yuan-Ting Chen
Franklin W Okumu
Youe-Kong Shue
Jonathan James Duffield
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1539977T3 publication Critical patent/DK1539977T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Claims (12)

1. Fremgangsmåde til fremstilling af tiacumicin B, omfattende: dyrkning af en mikroorganisme i et næringsmedium til akkumulering af tiacumicin B i næringsmediet; og isolering af tiacumicin B fra næringsmediet; hvor næringsmediet omfatter mindst én adsorberharpiks, der er i stand til at adsorbere tiacumicin B.
2. Fremgangsmåde ifølge krav 1, hvorved næringsmediet omfatter 0,5 vægt-% -15 vægt-% af den mindst ene adsorberharpiks, som er i stand til at adsorbere tiacumicin B.
3. Fremgangsmåde ifølge krav 1, der omfatter dyrkning af en mikroorganisme, der er i stand til at producere tiacumicin B i et næringsmedium omfattende mindst ét adsorberingsmiddel, som er i stand til at adsorbere tiacumicin B under dyrkningen, hvor adsorberingsmidlet udvælges fra gruppen bestående af en omvendt-fase-silicagel, Amberlite® XAD16, XAD16HP, XAD2, XAD7HP, XAD1180, XAD1600, IRC50 og Duolite XAD761, og akkumulering af tiacumicin B i næringsmediet.
4. Fremgangsmåde ifølge krav 1, hvorved mikroorganismen er Dactylosporangium aurantiacum NRRL 18085.
5. Fremgangsmåde ifølge krav 1, hvorved tiacumicin B isoleres fra næringsmediet under anvendelse af teknikker udvalgt fra gruppen bestående af: sigtning og fjernelse af uønsket materiale ved eluering med mindst ét opløsningsmiddel eller en opløsningsmiddelblanding; ekstraktion med mindst ét opløsningsmiddel eller en opløsningsmiddelblanding; krystallisation; kromatografisk separation; high-performance væskechromatografi (FIPLC); MPLC; triturering; og ekstraktion med mættet saltopløsning med mindst ét opløsningsmiddel eller en opløsningsmiddelblanding.
6. Fremgangsmåde ifølge krav 1, hvorved mikroorganismen dyrkes ved en temperatur fra ca. 25 °C til 35 °C og ved en pH fra ca. 6,0 til 8,0.
7. Fremgangsmåde ifølge krav 1, hvorved næringsmediet efter behov tilføres én eller flere carbonkilder, udvalgt fra gruppen bestående af glucose, saccharose, stivelse, melasse, dextriner, valle, glycerol, lipiderog majsmel.
8. Fremgangsmåde ifølge krav 1, hvorved næringsmediet efter behov tilføres en yderligere carbonkilde.
9. Fremgangsmåde ifølge krav 1, hvorved næringsmediet omfatter én eller flere nitrogenkilder/organiske kilder, der kan understøtte vækst af mikroorganismer, udvalgt fra gruppen bestående af kødekstrakt, sojabønnemel, helgær, gærekstrakt, sojamel, pepton, casaminosyre, fiskepulver, majsstøbevæske, ammoniumsalte, casein og aminosyrer.
10. Fremgangsmåde ifølge krav 9, hvorved næringsmediet omfatter fiskepulver.
11. Fremgangsmåde ifølge krav 1, hvorved næringsmediet omfatter ét eller flere uorganiske salte, der kan understøtte vækst af mikroorganismer, udvalgt fra gruppen bestående af K2FIPO4, MgSO^FhO og CaCC>3.
12. Fremgangsmåde ifølge krav 3, hvorved omvendt-fase-silicagelen udvælges fra gruppen bestående af KP-C18, KP-C 18-WP og KP-C18FIS.
DK03784766.2T 2002-07-29 2003-07-15 Fremstilling af tiacumicin DK1539977T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39995602P 2002-07-29 2002-07-29
PCT/US2003/021977 WO2004014295A2 (en) 2002-07-29 2003-07-15 Tiacumicin production

Publications (1)

Publication Number Publication Date
DK1539977T3 true DK1539977T3 (da) 2014-11-17

Family

ID=31715689

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03784766.2T DK1539977T3 (da) 2002-07-29 2003-07-15 Fremstilling af tiacumicin

Country Status (18)

Country Link
US (4) US7507564B2 (da)
EP (2) EP2860241A1 (da)
JP (3) JP2005534332A (da)
KR (1) KR100972542B1 (da)
CN (1) CN100519757C (da)
AU (1) AU2003251902B2 (da)
BE (1) BE2015C017I2 (da)
CA (1) CA2494742C (da)
CY (1) CY2015015I1 (da)
DK (1) DK1539977T3 (da)
ES (1) ES2527052T3 (da)
FR (1) FR15C0028I2 (da)
HU (1) HUS1500016I1 (da)
LU (1) LU92684I2 (da)
NL (1) NL300727I2 (da)
PT (1) PT1539977E (da)
SI (1) SI1539977T1 (da)
WO (1) WO2004014295A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1539977T3 (da) * 2002-07-29 2014-11-17 Optimer Pharmaceuticals Inc Fremstilling af tiacumicin
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
HUE027757T2 (en) * 2004-05-14 2016-11-28 Merck Sharp & Dohme Treatment of diseases associated with the use of antibiotics
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
KR101203118B1 (ko) * 2005-01-31 2012-11-20 옵티머 파마슈티칼즈, 인코포레이티드 18-원자 거대고리들 및 그 유사체들
AU2012200784B2 (en) * 2005-01-31 2013-07-11 Merck Sharp & Dohme Llc 18-membered macrocycles and analogs thereof
CA2626698C (en) * 2005-10-21 2015-12-01 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
KR100891313B1 (ko) * 2007-08-17 2009-03-31 (주) 제노텍 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
TWI326284B (en) * 2007-10-26 2010-06-21 Echem Hightech Co Ltd Derivatives of tiacumicin b as anti-cancer agents
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JP2013519380A (ja) * 2010-02-15 2013-05-30 アッヴィ・インコーポレイテッド ｓｃｙｌｌｏ−イノシトールを調製するための方法
AU2011316540A1 (en) 2010-10-13 2014-04-10 Elan Pharmaceuticals, Inc. Methods of synthesis of scyllitol and related compounds
CN102115757B (zh) * 2010-12-14 2015-10-28 中国科学院南海海洋研究所 台勾霉素的生物合成基因簇及其应用
ITMI20120559A1 (it) 2012-04-05 2013-10-06 Olon Spa Procedimento migliorato per la produzione di tiacumicina b
ITMI20120560A1 (it) * 2012-04-05 2013-10-06 Olon Spa Procedimento per la purificazione della tiacumicina b
CN104768963A (zh) * 2012-05-10 2015-07-08 特瓦制药厂有限公司 非达霉素的固态形式及其制备方法
ITMI20130856A1 (it) * 2013-05-27 2014-11-28 Olon Spa Procedimento per la produzione di tiacumicina b
WO2014023616A1 (en) * 2012-08-07 2014-02-13 Olon Spa Procedure for the production of tiacumicin b
ITMI20121406A1 (it) * 2012-08-07 2014-02-08 Olon Spa Procedimento per la produzione di tiacumicina b
CN102993251B (zh) * 2012-12-17 2016-03-16 苏州纳微科技有限公司 一种用高效液相色谱纯化台勾霉素b的方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
US10119158B2 (en) * 2013-04-23 2018-11-06 Concord Biotech Limited Process for the preparation of fidaxomicin
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103275153B (zh) * 2013-06-27 2016-03-23 华北制药集团新药研究开发有限责任公司 一种非达霉素晶体的制备方法
CN104418925B (zh) * 2013-09-05 2018-09-28 重庆乾泰生物医药有限公司 一种制备高纯度非达霉素的方法
CN104513286B (zh) * 2013-09-27 2018-08-17 博瑞生物医药（苏州）股份有限公司 一种分离纯化非达米星的方法
CN104560766B (zh) * 2013-10-16 2017-07-28 浙江海正药业股份有限公司 一种游动放线菌菌株及其应用
CN104561198B (zh) * 2013-10-18 2019-04-12 重庆乾泰生物医药有限公司 一种发酵生产非达霉素的方法
US20160319318A1 (en) * 2013-12-20 2016-11-03 Xellia Pharmaceuticals Aps Process for the preparation of tiacumicin
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
DK3119793T3 (da) 2014-03-18 2018-05-22 Xellia Pharmaceuticals Aps Nye polymorfer og nye faste tilstande af tiacumicin b
CN104946708B (zh) * 2014-03-28 2018-06-12 上海医药工业研究院 一种生产非达霉素的发酵培养基以及发酵方法
CN103880904B (zh) * 2014-03-28 2016-08-24 华北制药集团新药研究开发有限责任公司 非达霉素晶型i及其制备方法
PL3139932T3 (pl) 2014-05-09 2019-02-28 Astellas Pharma Europe Ltd. Schemat leczenia dla związku-tiakumycyny
CN104098637B (zh) * 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法
JP2018519344A (ja) 2015-07-03 2018-07-19 アステラス ファーマ ユーロープ リミテッド チアクマイシン化合物の新規の投薬レジメン
IL251499B (en) * 2017-04-02 2019-02-28 Efraty Avi Reverse osmosis installation in a closed circuit with a hydraulic arm for desalination with low energy consumption and a high recovery ratio
CN107236686B (zh) * 2017-06-21 2019-10-15 杭州华东医药集团新药研究院有限公司 一种桔橙指孢囊菌及其在调控微生物代谢物非达霉素中的应用
CN114084964B (zh) * 2020-08-24 2023-02-24 中国石油化工股份有限公司 一种芳香有机化合物废水生物处理促进剂及制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3000792A (en) 1957-05-21 1961-09-19 Merck & Co Inc Antibiotic adsorption process
GB1458512A (en) 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4632902A (en) * 1981-08-20 1986-12-30 Becton, Dickinson And Company Method for detecting biological activity in a body fluid
US4843008A (en) * 1984-12-24 1989-06-27 Yamanouchi Pharmaceutical Co., Ltd. Novel microorganisms and a novel process for producing antibiotics
US4918174A (en) * 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5242815A (en) * 1990-01-24 1993-09-07 Shin-Etsu Chemical Co., Ltd. Process for preparation of streptovaricin
CA2384523C (en) * 1991-03-04 2007-01-09 Bayer Corporation Automated analyzer
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
DK0941227T5 (da) * 1996-11-18 2009-10-05 Biotechnolog Forschung Gmbh Epothilon D, dens fremstilling samt dens anvendelse som cytostatisk middel og som plantebeskyttelsesmiddel
JP2000072760A (ja) * 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) * 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) * 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
ES2332727T3 (es) * 2000-04-28 2010-02-11 Kosan Biosciences, Inc. Epotilona d cristalina.
DK1539977T3 (da) * 2002-07-29 2014-11-17 Optimer Pharmaceuticals Inc Fremstilling af tiacumicin

Also Published As

Publication number Publication date
KR100972542B1 (ko) 2010-07-28
US7507564B2 (en) 2009-03-24
CA2494742A1 (en) 2004-02-19
US20060257981A1 (en) 2006-11-16
US20100028970A1 (en) 2010-02-04
FR15C0028I1 (da) 2015-05-15
KR20050053598A (ko) 2005-06-08
US20130123477A1 (en) 2013-05-16
EP1539977A4 (en) 2006-10-11
CN100519757C (zh) 2009-07-29
CN1688707A (zh) 2005-10-26
HUS1500016I1 (hu) 2017-10-30
NL300727I2 (da) 2016-05-17
EP1539977B1 (en) 2014-10-08
LU92684I2 (fr) 2015-11-02
US20140296498A1 (en) 2014-10-02
BE2015C017I2 (da) 2022-09-22
JP2010178760A (ja) 2010-08-19
SI1539977T1 (sl) 2015-01-30
FR15C0028I2 (fr) 2015-11-13
EP2860241A1 (en) 2015-04-15
CY2015015I1 (el) 2020-05-29
EP1539977A2 (en) 2005-06-15
CA2494742C (en) 2015-05-12
ES2527052T3 (es) 2015-01-20
JP5729919B2 (ja) 2015-06-03
US8728796B2 (en) 2014-05-20
WO2004014295A2 (en) 2004-02-19
AU2003251902B2 (en) 2008-03-06
JP2005534332A (ja) 2005-11-17
JP5907931B2 (ja) 2016-04-26
JP2013208131A (ja) 2013-10-10
AU2003251902A1 (en) 2004-02-25
PT1539977E (pt) 2015-01-14
WO2004014295A3 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
DK1539977T3 (da) Fremstilling af tiacumicin
JP2917305B2 (ja) Ｆｒ−９０１１５５物質およびその生産法
CZ390592A3 (en) Process for preparing 4,5-dihydrogendanamycin and hydroquinone thereof and the use of such compounds
WO2005038009A2 (en) Production of tacrolimus (fk-506) using new streptomyces species
EP0001709B1 (en) Deoxynarasin antibiotics, their production and use
JPH0763387B2 (ja) テイコプラニン‐様誘導体
JP3119680B2 (ja) 新規抗生物質バルヒマイシン、その製造方法およびそれを含有する抗菌剤
JPH04230399A (ja) 微生物の新規な免疫抑制発酵産物
JP3830964B2 (ja) 海洋放線菌から単離した新規なチオデプシペプチド
KR930001870B1 (ko) 신규의 항진균 물질 krf-001 복합체의 발효 및 정제방법
EP0818464B1 (en) Methylsulfomycin l, a process for its production and its use
CA2444907C (en) Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5
EP0531642B1 (en) Antibiotic LL-E19020 Zeta and LL-E 19029 Eta
US3549502A (en) Process for the production of neutramycin
JP2002212187A (ja) イソキノサイクリン系抗生物質
JP2000086627A (ja) 抗菌性物質ｂｅ−５４４７６及びその製造法
JPH03209384A (ja) 新規な微生物変換生成物
JPH0311096A (ja) 新規マクロライド抗生物質マイシナミシン類およびその製造法
JPH05255365A (ja) 抗生物質ＬＬ−Ｅ１９０２０エプシロン（ε）及びＬＬ−Ｅ１９０２０エプシロン１